

**COOPERATIVE RESEARCH AND DEVELOPMENT
AGREEMENT
WITH THE
UNITED STATES ENVIRONMENTAL PROTECTION AGENCY**

This Cooperative Research and Development Agreement ("CRADA" or "Agreement") is entered into by and between Water Gen, LTD, an Israeli Corporation which has its principal place of business at 11 Moshe Levi Street, Rishon LeZion 7565828, Israel ("the "Company" or "Water-Gen"), and the National Exposure Research Laboratory ("the Laboratory"), of the U.S. Environmental Protection Agency ("EPA") (collectively the "Parties") under the authority of Title 15, United States Code §§ 3710a-3710d (commonly known as the Federal Technology Transfer Act of 1986).

WITNESSETH:

A. WHEREAS, the Congress, in enacting the Federal Technology Transfer Act of 1986 (the "FTTA"), has found that Federal laboratories' developments should be made accessible to private industry, state and local governments, and has declared that one of the purposes of such Act is to improve the economic, environmental and social well-being of the United States by stimulating the utilization of Federally-funded technology developments by such parties;

B. WHEREAS, the FTFA provides each Federal agency with the authority to permit the Directors of Government-operated laboratories to enter into cooperative research and development agreements with Federal or non-Federal entities, including private firms and organizations for the purpose of providing to, or obtaining from, collaborating parties, personnel, services, property, facilities, equipment, intellectual property or other resources toward the conduct of specified research and development efforts, which may include the disposition of

patent or other intellectual property rights in the inventions resulting from such collaboration;

C. **WHEREAS**, the Laboratory has performed and has sponsored substantial research and development with respect to innovative water reuse approaches and technology;

D. **WHEREAS**, the Laboratory possesses certain advanced scientific skills, facilities, special equipment, information, computer software, and know-how pertaining to innovative water reuse approaches and technology;

E. **WHEREAS**, the Company has developed and is the sole owner of all intellectual property rights in connection with the GENius innovative patented technology and all other pending patents in connection therewith, and other confidential methods, trade secrets and know-how that are in use at and/or associated with atmospheric water generating (AWG) and dehumidifying technology (Hereinafter: the Company's "AWG technology" and the "Devices" or "WG Devices");

F. **WHEREAS**, the Laboratory and the Company are interested in collaborating for purposes of evaluating WG Devices for water quality and determining appropriate use scenarios for potential utilization by private and public entities, all subject to and in accordance with the Statement of Work, attached hereto as Annex A ("SOW"), and forming an integral part hereof;

G. **WHEREAS**, subject to the terms and conditions hereof, the Company is willing to provide one sample of the Devices, in accordance with the corresponding Material Transfer Agreement executed between the parties hereto, to the Laboratory: and,

H. **WHEREAS**, the Laboratory views its collaboration with the Company as set forth hereunder to evaluate the usefulness of atmospheric water generation technology generally, and specifically the

subject matter as set forth in the SOW to be in the furtherance of the public interest.

NOW, THEREFORE, the parties hereto agree as follows:

Article 1. Definitions

As used in this CRADA, the following terms shall have the following meanings and such meanings should be equally applicable to both the singular and plural forms of the terms defined:

1.1 "CRADA" or "Agreement" means this Cooperative Research and Development Agreement entered into by the Laboratory pursuant to 15 U.S.C. § 3710a.

1.2 "Computer Software" means computer software, computer programs, computer data bases, and documentation thereof developed, in whole or in part, under this Agreement.

1.3 "Government" means the Government of the United States of America.

1.4 "Invention" means any invention or discovery which is or may be patentable or otherwise protectable under the intellectual property laws of this or any foreign country.

1.5 "Made" in relation to any Invention means the conception or first actual reduction to practice of such Invention.

1.6 "Intellectual Property" means intellectual property rights of any nature whatsoever, including without limitation - patents, patent applications, copyright, design, design rights, internet domain names, database rights, trademarks, service marks or business names, applications to register any of the aforementioned rights, and in each case in any part of the world and whether or not registered;

"Proprietary Information" means know-how, technical and commercial information, trade secrets and rights of confidence, including which embodies trade secrets developed at private expense, or which is confidential scientific, business or financial information, excluding such information which is already in the public domain as of the execution date hereunder through no breach of any Party hereunder and/or any third party; and,

"Confidential Information" means any and all written, electronic, oral or visual information of the Disclosing Party that is not in the public domain, including without limitation - any information pertaining to its business, facilities, operations, organizations, products, technologies, algorithms, customers, suppliers, engineering/design specifications, drawings, manufacturing know-how, cost/price data, intellectual property rights, trade secrets, business processes, business data, plans and strategies (including the AWG technology and any other material or know-how related thereto), all whether prepared by the Disclosing Party, its representatives or otherwise, in any media, form or shape whatsoever and whether disclosed before or after the execution date of this Agreement.

1.7 "Subject Data" means all information produced in the performance of the work hereunder. This term includes Computer Software.

1.8 "Subject Invention" means any Invention conceived or first actually reduced to practice in the performance of work under this Agreement.

1.9 "Technology" means atmospheric water generation (AWG) technology, generally.

1.10 "Works" means any Computer Software or subject matter that is copyrightable.

Article 2. Statement of Work and Manner of Cooperation

2.1 Statement of Work. Cooperative research and development work to be performed under this Agreement shall be performed in accordance with the Statement of Work ("SOW") attached hereto as **Annex A.** The SOW sets forth a period of performance. The Laboratory and the Company agree to use their best efforts with the aim to perform the work hereunder and to utilize such personnel, resources, facilities, equipment, skills, know-how and information as is reasonably necessary.

2.2 Review of Work. Periodic conferences shall be held between Laboratory and Company personnel for the purpose of reviewing the progress of the work to be accomplished under this Agreement. While the Company's Project Manager and accompanying Company personnel are welcome guests of the Laboratory, and are expected to be present and to participate, the Laboratory shall have exclusive control and supervision over the conduct of all cooperative research and development work conducted at the Laboratory facilities. The Company shall have exclusive control and supervision over the conduct of all cooperative research and development work conducted at the Company facilities. It is understood that the nature of the parties' cooperation hereunder is such that completion within the period of performance specified in the SOW or within the limits of financial support allocated, cannot necessarily be guaranteed. Accordingly, it is agreed that all cooperative work is to be performed hereunder on a best efforts basis in accordance with the SOW.

2.3 Assigned Personnel. Each party to this Agreement shall perform its respective obligations under this Agreement through their respective representatives. The parties designate the following individuals as their respective representatives:

Laboratory

Project Manager
Principal Investigator

NERL
NERL

Michael Nye
Jay L. Garland

Company

Project Manager

Avi Perez

2.4 Scope Change. If at any time the Project Managers determine that the Subject Data justify a substantial change in the direction of the work, the parties shall make a good faith effort to mutually agree on any necessary changes to the SOW. Any such changes to be mutually agreed upon between the Parties shall be recorded in writing, and shall form an amendment of the SOW.

2.5 Security protocols.

(a) The Laboratory shall ensure that the WG Device will be placed in a reasonably protected premises at all times to ensure uninterrupted use. The Laboratory shall be solely responsible for power supply and/or generators as may be required for the on-going operation of the WG Device. The Laboratory agrees to follow all security, technical and operations requirements and policies of the Company as shall be communicated by the Company or its representative at all times.

(b) The Laboratory acknowledges that nothing herein shall be construed as granting the Laboratory with any proprietary right, or any other intellectual property right in and/or to any of the WG Devices and/or any of its components and/or any of the technology and know-how underlying the technology upon which the WG Devices are based.

(c) The Laboratory agrees to use, handle, store and transport the WG Device in line with applicable U.S. laws and regulations, and act according to necessary safety rules under applicable U.S. laws, and reasonable instruction provided by the Company;

(d) The Laboratory agrees to take all actions necessary to make the WG Device available for shipment back to Company's facility at the conclusion of the CRADA, or at the Company's first request. The Laboratory agrees to comply with the Company's procedures relating to delivery and shipment of the WG Devices;

(e) The Company is and shall remain the sole owner of the WG Device which is being provided hereunder.

Article 3. Reports

3.1 Final Report. The Laboratory shall submit a final report to the Company of the Laboratory's results within 60 calendar days after (a) completing the SOW, or (b) the termination of this Agreement. Likewise, the Company shall submit a final report to the Laboratory of the Cooperator's results within 60 calendar days after (a) completing the SOW, or (b) the termination of this Agreement, if applicable.

Article 4. Financial Obligations

No funds are anticipated to be collected from the Company in the course of this effort. The Company shall incur all costs and expenses associated with the delivery of the WG Devices to and back from the Laboratory's designated facilities at the end of the CRADA.

4.1 Assignment of Personnel. The Company shall provide the services of a qualified representative who will assist in the efforts under the SOW in **Annex A**. The representative shall be an employee of the Company and shall be available to remotely participate in project discussions, meetings and briefings with EPA personnel and periodically travel to the EPA facilities located in Cincinnati, Ohio, Research Triangle Park, NC or Washington, DC in the course of executing the SOW.

Article 5. Invention, Computer Software, and Patent Rights

Each Party acknowledges and agrees that the other Party shall remain at all times the sole and exclusive owner of its Intellectual Property and nothing in this Agreement shall be construed or interpreted as a transfer or grant of any right, title, license or other interest in any of the other Party's Intellectual Property.

5.1 Reporting. The Laboratory shall promptly report to the Cooperator each Subject Invention reported to the Laboratory by its employees. The Cooperator shall promptly report to the Laboratory each Subject Invention reported to the Cooperator by any of its employees.

5.2 Government's Minimum Rights. All assignments made by the Laboratory under this Article 5 and all licenses granted by the Laboratory to the Company are subject to the reservation of statutorily required licenses in favor of the Government as described in this paragraph 5.2. In accordance with 15 U.S.C. §§ 3710a(b)(2) and (b)(3)(D), the Company grants to the Laboratory a nonexclusive, nontransferable, irrevocable, paid-up license to practice all Company Subject Inventions or have all Company Subject Inventions practiced throughout the world on behalf of the Government. Also in accordance with 15 U.S.C. § 3710a(b)(1) the Laboratory retains a nonexclusive, nontransferable, irrevocable, paid-up license to practice all the Laboratory and joint Subject Inventions or have the Laboratory and joint Subject Inventions practiced, throughout the world by or on behalf of the Government.

5.3 Company Employee Inventions. The Company shall obtain from each of its employees and each of the employees of its subcontractors who will, or is likely to perform work under this Agreement, an agreement to assign to the Company his or her rights to Subject Inventions. Regardless of whether such a prospective agreement has been obtained, the Company shall obtain from any of its employees

or its subcontractor's employees that is a sole inventor or a co-inventor of a Subject Invention, an assignment of all domestic and foreign right, title and interest in said Subject Invention. The Company shall retain its intellectual property rights to any Subject Invention made by Company employees or the employees of the Company's subcontractor. If the Company decides to not retain its rights, the Company shall offer to assign its rights to the Subject Invention to the Laboratory, subject to a paid-up license to practice the assigned Subject Invention throughout the world. If the Laboratory declines such assignment, the Company may release its right to employee inventors, subject to the reservation of patent licenses in favor of the Government as required in paragraph 5.2 above.

5.4 Laboratory Employee Inventions. The Laboratory shall obtain from each of its employees that is a sole inventor or a co-inventor of a Subject Invention an assignment to the Government, as represented by the Administrator of EPA, of all domestic and foreign right, title and interest in said Subject Invention. If the Laboratory decides not to retain its rights to a Subject Invention, the Laboratory shall offer to assign its rights to the Subject Invention to the Company, subject to the reservation of patent licenses in favor of the Government as required in paragraph 5.2 above. If the Company declines such assignment, the Laboratory may release its rights to its employee inventors.

5.5 Inventions by the Laboratory's Contractors. The Cooperator agrees that the Laboratory may contract with a contractor to perform all or part of the work required under the SOW. The Laboratory shall, in any new contract or work assignment supporting the Agreement, include alternate paragraph (b) in the basic patent rights clause at 37 C.F.R. 401.14(c), under which the Laboratory may require the contractor to negotiate a license with the Company for rights to the subject invention. If EPA obtains an assignment of rights to a subject invention developed by a contractor during the performance of a contract for work supporting the Agreement, the EPA shall grant the Company a license in accordance with Section 5.10.1 of this Agreement.

In the case of a Laboratory contract or work assignment awarded prior to the effective date of this Agreement, which contains one or more provisions that prevent acquisition of a license or title to Subject Inventions by the Company, Laboratory, or EPA, the Laboratory and EPA agree that they will exert a good faith effort to amend the contract or work assignment in a way consistent with the preceding paragraph; provided, however, that if the Laboratory or EPA should fail to bring about the necessary amendment or assignment of rights, the Laboratory and EPA shall not be liable for a breach of this Agreement, nor shall such failure be a basis for termination of this Agreement by the Company.

5.6 Filing of Patent Applications. The party retaining title to a Subject Invention shall file patent applications in a timely manner; the Company shall be responsible for filing patent applications for joint Subject Inventions between the Company and the Laboratory in a timely manner. The filing party may elect not to file a patent application in any particular country or countries provided it so advises the other party ninety (90) calendar days prior to the expiration of any applicable filing deadline, priority period, or statutory bar date. The party electing not to file shall assign its intellectual property right, title, and interest in such country or countries to the Subject Invention to the other party and shall cooperate in the preparation and filing of patent applications, provided the other party agrees to file a patent application in such country or countries. Any license or assignment by the Government to the Company shall be subject to reservation of patent licenses in favor of the Government as required in paragraph 5.2. Any license or assignment by the Company to the Government shall be subject to reservation of a paid-up license in favor of the Company to practice the assigned Subject Invention throughout the world.

5.7 Patent Expenses. All of the expenses attendant to the filing of patent applications shall promptly be paid by the party filing such application. Any post filing and post patent fees shall also be borne by

the same party. If the Company obtains an exclusive license of the Government's interest in a patent or patent application filed by the Laboratory, the Company shall reimburse the Laboratory for all such patent filing, post filing and post patent expenses paid by the Laboratory. If the Company obtains a nonexclusive license of the Government's interest in a patent or patent application filed by the Laboratory, the Company shall reimburse the Laboratory for one-half of all such filing and other patent expenses.

5.8 Prosecution of Patent Applications. Each party to this Agreement shall promptly provide the other party with copies of any patent application it files on any Subject Invention, and a copy of each action received from a patent office and each item of correspondence with a patent office. The parties agree to consult and cooperate with each other in obtaining and maintaining protection for Subject Inventions. In addition, on request, each party that has filed a patent application shall issue to the other party a "Power to Inspect and Make Copies" in any patent office of any identified patent application.

5.9 Cooperator and Laboratory Employee Rights. In the event that the Cooperator and the Laboratory decide that a patent application on a particular Subject Invention need not be filed in a particular country, either or both (if there are co-inventors from each party) may, at their sole discretion and subject to reasonable conditions, allow the inventor(s) to retain title to that Invention and release to them the right to file. Such conditions shall include nonexclusive, irrevocable, paid-up licenses to the Cooperator and the Government to practice, or have practiced, that Subject Invention throughout the world. Said licenses shall be evidenced by a confirmatory license in a form acceptable to the Cooperator and the Government.

5.10 Exclusive License

5.10.1 Grant. The Laboratory, on behalf of the Government, hereby grants to the Company a first option to an exclusive license of the

Government's interest in each Subject Invention and in any resulting patents issued on such Subject Invention. This option may be exercised not later than thirty-six (36) months following the filing of a patent application on the Subject Invention in the U.S. Patent and Trademark Office pursuant to paragraph 5.6, above.

5.10.2 Exclusive License Agreement. Upon notice received by the Laboratory from the Cooperator that it wishes to exercise the option referred to in paragraph 5.10.1 above, the terms of the exclusive license will be negotiated promptly in good faith by the Laboratory and the Company, and may include a reasonable royalty to the Government that is customary in the industry. Any exclusive license will be subject to the reservation by the Government of a non-exclusive, irrevocable, paid-up license to practice or have practiced on its behalf the Subject Invention throughout the world, for non-commercial purposes.

5.11 Computer Software and Copyrightable Works

5.11.1 Reporting. The Laboratory shall promptly report to the Company any Computer Software or subject matter that is copyrightable ("Works") created by its employees and, to the extent it has the right to do so, Works made by any of its contractors. The Company shall promptly report to the Laboratory any Works created by any of its employees or contractors.

On request from the Laboratory, the Company shall deliver to the Laboratory a copy of such Works in a form mutually agreed to by the Laboratory and the Cooperator.

5.11.2 Laboratory Employee Developed Works. In view of the provisions of 17 U.S.C. § 105, any Works developed solely by one or more employees of the U.S. Government, as part of their official duties, cannot be protected by copyright in the U.S.

5.11.3 Company Developed Works. In the case of Works developed solely by (an) employee(s) of the Company, the Company shall advise the Laboratory, within six (6) months of reporting such Works, pursuant to paragraph 5.11.1 above, whether it wishes to retain title thereto.

If the Company elects to not retain title to its Works, on written request from the Laboratory, it will assign its rights, including any copyright, to the Laboratory. The Laboratory shall provide the Company with an appropriate document for the conveyance of such rights.

If the Company elects to retain title to its Works, it may assert copyright thereto and/or patent rights, if applicable. If the Company asserts copyright to said Works, it hereby grants to the U.S. Government and others acting on its behalf a nonexclusive, irrevocable, paid-up worldwide license in such copyrighted Works to use, reproduce, distribute, prepare derivative works, perform publicly and display publicly the Work.

5.11.4 Laboratory and Company Jointly Developed Works. If the Company wishes to retain ownership of its copyright interest in the Works, and wishes to rely on copyright protection, it may do so, subject to the Government license in 5.11.3 above, and subject to the provisions of Title 17, U.S. Code, Section 105.

5.11.5 Patenting of Computer Software. In the event the Company seeks patent protection for Computer Software developed either solely by its employees or jointly with Laboratory employees, the foregoing provisions applicable to Subject Inventions shall also apply to such Computer Software.

5.11.6 Patent and Copyright Protection for Computer Software. If the Company seeks both patent protection and copyright

protection, the rights of the Government shall be those applicable to Subject Inventions and Copyrightable Subject Matter.

5.11.7 Works Produced by Laboratory Contractors or EPA Contractors. The Laboratory, to the extent permitted by law and/or the Federal Acquisition Regulations at Title 48, C.F.R., shall include FAR clause 52.227-17 in any contract awarded after the effective date of this Agreement, which provides that any rights to copyrights for data first produced under the contract may be assigned to EPA by the contractor. If EPA obtains such rights to Computer Software developed by the contractor while performing work designated by the Laboratory as work under this Agreement, the Laboratory agrees that it will provide the Company a non-exclusive, irrevocable, paid-up worldwide license to the copyrighted work, including the right to reproduce, distribute, prepare derivative works, perform publicly, and display publicly the Work.

In the case of a Laboratory contract awarded prior to the effective date of this Agreement, which contains one or more provisions that prevent acquisition of title to computer software by the Laboratory or EPA, the Laboratory and EPA agree that they will exert a good faith effort to amend the contract in such a way as to obtain an assignment of the copyright; provided however, that if the Laboratory or EPA should fail to bring about the necessary amendment, the Laboratory and EPA shall not be liable for a breach of this Agreement, nor shall such failure be a basis for termination of this Agreement by the Company.

Article 6. Data and Publication

6.1 Proprietary Information & Confidential Information. Information designated as Confidential Information and Proprietary Information shall not be disclosed, copied, reproduced or otherwise made available in any form whatsoever to any other person, firm, corporation, partnership, association or other entity without consent of the Company, except as such information may be subject to disclosure under the Freedom of Information Act (5 U.S.C. § 552), and EPA's

regulations at 40 C.F.R. Part 2, or as required to be disclosed by other statutes. The Company agrees that the Laboratory is not liable for the disclosure of Proprietary Information which, after notice to and consultation with the Company, EPA determines may not lawfully be withheld or which a court of competent jurisdiction requires to be disclosed.

6.2 Release Restrictions. The Laboratory shall have the right to use all Subject Data for any Governmental purpose. The Laboratory shall not release any Subject Data publicly or provide such Subject Data to any Government regulatory body or agency other than the EPA, except:

- (a) the Laboratory in reporting the results of cooperative research may publish Subject Data, subject to the provisions of paragraph 6.3 below, and provided the Company is given 45 days to review the manuscript and provide suggestions before publication;
- (b) The Company in reporting the results of cooperative research may publish Subject Data, subject to the provisions of paragraph 6.3 below, and provided the Laboratory is given 45 days to review the manuscript and provide suggestions before publication;
- (c) the Laboratory may release such Subject Data where such release is required pursuant to a request under the Freedom of Information Act (5 U.S.C. § 552) and the EPA regulations at 40 C.F.R. Part 2 or as required to be disclosed by other statutes;
- (d) Pursuant to 35 U.S.C. § 205, neither the Laboratory nor the Company shall release to the public any Subject Data or other data that discloses or enables an invention if a patent application is to be filed, until the party having the right to file a patent application or provisional patent application has had a reasonable time to file.

6.3 Publication. The Laboratory and the Company agree to confer and consult prior to the publication of Subject Data to ensure that no Confidential Information or Proprietary Information is released and that patent rights are not jeopardized. Prior to submitting a manuscript for outside review which contains the results of the research under this Agreement, or prior to publication if no such review is made, each party shall be offered at least 45 calendar days to review such proposed publication and to file patent applications in a timely manner, if it is so entitled or required under this Agreement.

Article 7. Representations and Warranties

7.1 Representation and Warranties of the Laboratory. The Laboratory hereby represents and warrants to the Company as follows:

7.1.1 Organization. The Laboratory is a Federal laboratory of the EPA and is wholly owned by the Government. The Laboratory's substantial purpose is the performance of research or development.

7.1.2 Mission. The performance of the activities specified by this Agreement is consistent with the mission of the Laboratory.

7.1.3 Authority. All prior reviews and approvals required by Federal regulations and laws have been obtained by the Laboratory prior to the execution of this Agreement. The Laboratory official executing this Agreement has the requisite authority to do so.

7.2 Representations and Warranties of the Company. The Company hereby represents and warrants to the Laboratory as follows:

7.2.1 Corporate Organization. The Company, as of the date hereof, is a corporation duly organized, validly existing, and in good standing under the laws of Israel.

7.2.2 Power and Authority. The Company has the requisite power and authority to enter into this Agreement and to perform according to the terms thereof.

7.2.3 Due Authorization. The Board of Directors and stockholders of the Company have taken all actions, if any, required to be taken by law, the Company's Certificate or Articles of Incorporation, its bylaws or otherwise, to authorize the execution and delivery of this Agreement.

7.2.4 No Violation. The execution and delivery of this Agreement do not contravene any material provision of, or constitute a material default under, any material agreement binding on the Company or any valid order of any court, or any regulatory agency or other body having authority to which the Company is subject, nor, to the best of its knowledge, is the Company the subject of any adversarial proceeding by any regulatory governmental agency.

Article 8. Termination

8.1 Termination by Mutual Consent. The Laboratory and the Company may elect to terminate this Agreement, or portions thereof, at any time by prior written mutual consent. Upon termination by such mutual consent, the Laboratory, as of the termination date, shall make no new commitments, and as soon after the termination date as feasible, shall cancel all outstanding commitments that relate to those portions of this Agreement that have been mutually terminated.

8.2 Termination by Unilateral Action. Either party may unilaterally terminate this entire Agreement at any time by giving the other party written notice not less than 90 calendar days prior to the desired termination date. The Laboratory shall make no new commitments after receipt of a written termination notice from the Cooperator and shall to the extent possible, by the termination date,

cancel all outstanding commitments and contracts that were entered into as a consequence of the requirements of the SOW in Attachment A.

8.3 Termination Costs. Each party shall pay its own termination costs out of its own funds. Any funds furnished by the Company which are unexpended or unobligated as of the date of termination will be returned to the Company. In no event shall either party be liable for the direct and indirect termination costs of the other party or said other party's expenses caused by or related to the termination.

8.4 Survival. To the extent rights and obligations hereunder have accrued as of the date of expiration or termination, the following Articles of this Agreement shall survive any expiration or termination hereof: 5, 6, and, 10, and any expiration or termination hereof shall not affect any license granted hereunder.

Article 9. Disputes

9.1 Settlement. Any dispute arising under this Agreement which cannot be readily resolved shall be submitted jointly to the signatories of this Agreement. A joint decision of the signatories or their designees shall be the disposition of such dispute. If the signatories are unable to jointly resolve a dispute within a reasonable period of time after submission of the dispute for resolution, the matter shall be submitted to the Administrator of EPA or the Administrator's designee for resolution. Such resolution may be appealed in a Federal court of competent jurisdiction.

Article 10. Liability

10.1 EPA. EPA's responsibility for the payment of claims to the Company or its employees for loss of property, personal injury or death caused by the negligence or the wrongful act or omission of employees of EPA, while acting within the scope of their employment, is in

accordance with the provisions of the Federal Tort Claims Act, 28 U.S.C. §§ 2671-80 and 40 C.F.R. Part 10.

10.2 No Warranty. Except as specifically stated in Article 7, neither party makes any express or implied warranty as to any matter whatsoever, including the conditions of the research or as to any Invention made or product developed, or the ownership, merchantability, or fitness for a particular purpose, of the research or any such Invention or product.

10.3 Force Majeure. Neither party shall be liable for any event or circumstance beyond its reasonable control not caused by the fault or negligence of such party, which causes such party to be unable to perform its obligations under this Agreement (and which it has been unable to overcome by the exercise of due diligence), including but not limited to flood, drought, earthquake, storm, fire, pestilence, lightning and other natural catastrophes, epidemic, war, riot, civil disturbance or disobedience, strikes, labor dispute, sabotage of the Laboratory facilities, or any order or injunction made by a court or public agency. In the event of the occurrence of such a force majeure event, the party unable to perform shall promptly notify the other party. It shall further use its best efforts to resume performance as quickly as possible and shall suspend performance only for such period of time as is necessary as a result of the force majeure event.

10.4 Company. The Company agrees that during the term of this Agreement it will carry liability insurance in the amount set forth on the attached certificate of insurance to cover any liability to the Government or to Government employees and private individuals that may arise as a result of negligent acts or omissions of any of the Company's employees or agents while they are performing work under this Agreement including any work which such employee or agent may be performing at the Laboratory.

Article 11. Miscellaneous

11.1 No Benefits. No member of, or delegate to the United States Congress, or resident commissioner, shall be admitted to any share or part of this Agreement, nor to any benefit that may arise therefrom. This provision shall not be construed to extend to this Agreement if the Agreement is made with the Company for the Company's general benefit.

11.2 Governing Law. The construction, interpretation, validity, performance and effect of this Agreement for all purposes shall be governed by the laws applicable to the federal government of the United States.

11.3 Headings. Titles and headings of the Sections and Subsections of this Agreement are for the convenience of references only and do not form a part of this Agreement and shall in no way affect the interpretation thereof.

11.4 Waivers. None of the provisions of this Agreement shall be considered waived by any party hereto unless such waiver is given in writing to all other parties. The failure of any party to insist upon strict performance of any of the terms and conditions hereof, or failure or delay to exercise any rights provided herein or by law, shall not be deemed a waiver of any rights of any party hereto.

11.5 Severability. The illegality or invalidity of any provisions of this Agreement shall not impair, affect or invalidate the other provisions of this Agreement.

11.6 Amendments. If either party desires a modification to this Agreement, the parties shall, upon reasonable notice of the proposed modification by the party desiring the change, confer in good faith to determine the desirability of such modification. Such modification shall not be effective until a written amendment is signed by all the parties

hereto by their representatives duly authorized to execute such amendments.

11.7 Assignment. Except as otherwise permitted herein, neither this Agreement nor any rights or obligations of any party hereunder shall be assigned or otherwise transferred by either party without the prior written consent of the other party. However, the Company may assign this Agreement to the successors or assignees of a substantial portion of the Company's business interests to which this Agreement directly pertains.

11.8 Notices. All notices pertaining to or required by this Agreement shall be in writing and shall be signed by an authorized representative and shall be delivered by hand or sent by certified mail, return receipt requested, with postage prepaid, addressed as follows:

(a) If to LABORATORY:

Authorized Representative:

Timothy H. Watkins
Director, National Exposure Research Laboratory
109 TW Alexander Dr. Research Triangle Park, NC 27709
Phone: 919 541-3658
Email: watkins.tim@epa.gov

With a copy to:

Jay L. Garland, Ph.D.
Director, Systems Exposure Division
26 West Martin Luther King Drive, Cincinnati, OH 45220
Phone: 513-569-7334
Email: garland.jay@epa.gov

AND

Sarah Bauer
FTTA Program Manager
 (Overnight courier address)
 US EPA MC 8106R
 Ronald Reagan building Room 71175
 1300 Pennsylvania Ave NW
 Washington, DC 20004
 Phone: 202-564-3267
 Email: bauer.sarah@epa.gov

(b) If to COMPANY:

Authorized Representative (signator):

Name: Maxim Pasik
 Title: Executive Chairman, Water Gen, Israel
 Address: 11 Moshe Levi Street, Rishon LeZion 7565828, Israel
 Phone: +972-3-9416861/2
 Email: maxim@water-gen.com

With a copy to (PI or other):

Name: Avi Peretz
 Title: Co-CEO, Water-Gen
 Address: 11 Moshe Levi Street, Rishon LeZion 7565828, Israel
 Phone: +972-54-250-7505
 Email: avi@water-gen.com

Any party may change such address by notice given to the other party in the manner set forth above.

11.9 Independent Parties. The relationship of the Laboratory and the Company is that of independent parties and not as agents of each other or as joint venturers or partners. The Laboratory shall maintain sole and exclusive control over its personnel and operations. The Company shall maintain sole and exclusive control over its personnel and operations.

11.10 Use of Name or Endorsements. The Company shall not use the name of the Laboratory or EPA, on any product or service which is directly or indirectly related to either this Agreement or any patent license or assignment agreement which implements this Agreement, without the prior approval of the Laboratory. By entering into this Agreement the Laboratory does not directly or indirectly endorse any product or service provided, or to be provided, by the Company, its successors, assignees, or licensees. The Company shall not in any way imply that this Agreement is an endorsement of any such product or service. This section in no way prohibits the publication of any EPA indication or statement regarding the efficacy of any Subject Invention and/or any other results of this Agreement.

11.11 No Approval. Nothing in this Agreement shall be deemed to constitute regulatory or scientific approval of the use of any particular product or technology. The Company agrees that (a) nothing in this Agreement relieves it of any obligation to comply with applicable federal, state, or local laws, regulations, or requirements, and (b) possession or acquisition by the Laboratory of Subject Data, or other information generated or otherwise acquired pursuant to performance of work under this Agreement, does not constitute knowledge of or possession or receipt of such data or information by or on behalf of the Administrator of the Environmental Protection Agency for purposes of statutory or regulatory reporting requirements such as, but not limited to, Section 8 of the Toxic Substances Control Act.

11.12 Human Subjects (if applicable). The Company agrees to comply with all applicable provisions of EPA Regulation 40 CFR 26 (Protection of Human Subjects). This includes, at Subpart A, the Basic Federal Policy for the Protection of Human Research Subjects, also known as the Common Rule. It also includes, at Subparts B, C, and D, prohibitions and additional protections for children, nursing women, pregnant women, and fetuses in research conducted or supported by EPA. The Company further agrees to comply with EPA's procedures

for oversight of the Company's compliance with 40 CFR 26, as given in EPA Order 1000.17 Change A1: Policy and Procedures on Protection of Human Research Subjects in EPA Conducted or Supported Research.

11.13 Entire Agreement. This Agreement constitutes the entire agreement between the parties concerning the subject matter hereof and supersedes any prior understanding or written or oral agreement relative to said matter.


Article 12. Duration of Agreement and Effective Date

12.1 Effective Date. This Agreement shall enter into force as of the date of the last signature of the parties.


12.2 Duration. This Agreement shall remain in effect for a period of 2 years from the effective date.

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives as follows:

U.S. ENVIRONMENTAL PROTECTION AGENCY

By:  Date: 1/10/18
Timothy H. Watkins
Director, National Exposure Research Laboratory

THE COMPANY

By:  Date: 1/14/2018
WATER-GEN LTD
C.N. 514300375
Maxim Pasik
Executive Chairman